Pipeline

We are developing a differentiated portfolio of intratumorally and intravenously administered viral immunotherapies across our Herpes Simplex Virus (HSV) and selectively self-amplifying viral RNA (vRNA) Immunotherapy Platforms. This will enable us to pursue multiple indications with the potential to transform outcomes for more cancer patients.
Platform
Therapy
Indications
Development Stage
Research
IND-enabling
Phase 1
Phase 2
Phase 3
Commercial Rights
Herpes Simplex Virus

(Intratumoral)

Herpes Simplex Virus
(Intratumoral)
ONCR-177 Melanoma
SCCHN
TNBC

Monotherapy and in Combination with

ONCR-177
Herpes Simplex Virus
(Intratumoral)
ONCR-GBM Glioblastoma multiforme
Other CNS tumors
ONCR-GBM
Selectively Self-Amplifying vRNA

(Intravenous)

Selectively Self-Amplifying vRNA
(Intravenous)
ONCR-021 NSCLC
HCC
ccRCC
Melanoma
ONCR-021
Selectively Self-Amplifying vRNA
(Intravenous)
ONCR-788 SCLC
Prostate and other neuroendocrine tumors
ONCR-788
ccRCC = clear cell renal cell carcinoma; CNS = central nervous system; GBM = glioblastoma multiforme; HCC = hepatocellular carcinoma; IND = investigational new drug; I/O = immuno-oncology; MSS CRC = microsatellite stable colorectal cancer; NSCLC = non-small cell lung cancer; SCCHN = squamous cell carcinoma of the head and neck; SCLC = small cell lung cancer; TNBC = triple negative breast cancer; vRNA = viral RNA If you are interested in partnering with Oncorus, please contact us.